Harmine inhibits oxidative phosphorylation, thus regulating the polarization of macrophages mediated by extracellular adenosine in endometriosis
Lab / animal
OA: closed
CC0
AI-generated summary
Harmine inhibits oxidative phosphorylation and extracellular adenosine production in endometriotic cells, promoting M1 macrophage polarization and reducing lesion size in a mouse model.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
STUDY QUESTION: Can harmine mitigate endometriosis by modulating oxidative phosphorylation (OXPHOS) suppression and macrophage polarization?
SUMMARY ANSWER: Harmine induces apoptosis in endometriotic lesions by inhibiting OXPHOS while also modulating macrophage polarization through the reduction of extracellular adenosine (eADO), a metabolic byproduct of OXPHOS.
WHAT IS KNOWN ALREADY: Endometriosis is associated with mitochondrial dysfunction while ectopic endometrial stromal cells (EESCs) exhibit heightened susceptibility to oxidative stress. Macrophages accumulate in the peritoneal cavity and peritoneal fluid, constituting a dominant immune cell population within endometriotic lesions.
STUDY DESIGN, SIZE, DURATION: A total of 25 patients diagnosed with ovarian endometriosis and 25 healthy donors undergoing surgical treatment at a university-affiliated hospital within 6 months were included. Primary normal endometrial stromal cells (NESCs) and EESCs were isolated, cultured, and subjected to pharmacological drug intervention, small interfering RNA (siRNA) transfection, OXPHOS analysis, and transcriptomic profiling. Macrophage cell line RAW264.7 was used to study macrophage polarization. The in vivo study involved 24 C57BL/6 female mice to establish an endometriosis model.
PARTICIPANTS/MATERIALS, SETTING, METHODS: The impact of harmine on cellular viability in vitro was assessed using Cell Counting Kit-8 (CCK-8) clonogenic assays, 5-ethynyl-2'-deoxyuridine (EdU) incorporation, and flow cytometry. OXPHOS inhibition was evaluated through mitochondrial ultrastructural changes observed via transmission electron microscopy and fluorescence staining. Oxidative stress was quantified using JC-1 mitochondrial membrane potential assays and reactive oxygen species (ROS) detection kits. Seahorse oxygen consumption rate assay was conducted to measure OXPHOS activity. Immunohistochemistry was employed to examine key protein expression in endometrial tissues. ATP and eADO levels were quantified using an ATP Assay Kit and Adenosine Assay Kit, respectively. We used RNA sequencing (RNA-seq) to identify enriched biological pathways. Flow cytometry was used to characterize macrophage populations in peritoneal fluid, and CIBERSORTx software was applied to generate immune cell expression profiles. Samples with P-values <0.05 were selected for analysis, with macrophage subtype (Mφ2/Mφ1) alterations statistically evaluated using the Wilcoxon test.
MAIN RESULTS AND THE ROLE OF CHANCE: EESCs exhibited greater susceptibility to harmine treatment compared to NESCs (P < 0.05). RNA-seq analysis revealed that harmine primarily influences pathways related to cell proliferation, oxidative stress, and HIF-1 signaling. Differentially expressed genes were enriched in complexes regulating mitochondrial OXPHOS. Harmine intervention significantly increased mitochondrial fission in EESCs compared to NESCs and markedly suppressed OXPHOS activity in EESCs. Treatment with harmine decreased total ROS levels in cultured EESCs (P < 0.05 vs NESCs). The eADO/CD73-mediated adenosine pathway was upregulated in endometriotic lesions, accompanied by a predominance of Mφ2 macrophages in the microenvironment (Wilcoxon test, P < 0.05). In the murine model, harmine treatment decreased eADO production and shifted macrophage polarization toward a pro-inflammatory Mφ1 phenotype, contributing to endometriotic lesion regression.
LARGE SCALE DATA: N/A.
LIMITATIONS, REASONS FOR CAUTION: The study's reliance on primary cells was constrained by their limited passage potential and inherent heterogeneity, precluding co-culture investigations. Further mechanistic elucidation requires cell line-based studies. More subtypes should be included in the research, not just models of ovarian endometriosis. Eutopic endometrial cells should be included in the experiment if conditions permit. Additionally, primate models with menstrual cycles, such as rhesus monkeys, should be considered for future in vivo validation.
WIDER IMPLICATIONS OF THE FINDINGS: These findings indicate that harmine may serve as a promising alkaloid-based therapeutic for endometriosis by modulating energy metabolism and immune responses.
STUDY FUNDING/COMPETING INTEREST(S): This research was supported by the National Natural Science Foundation of China (NSFC No. 82201814), the Guangdong Basic and Applied Basic Research Foundation (2021A1515110444), and the Foundation of Shenzhen Hospital of Southern Medical University (PY2022YM03). The authors declare no conflicts of interest.
TRIAL REGISTRATION NUMBER: N/A.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (47)
- Can Endometriosis-Related Oxidative Stress Pave the Way for New Treatment Targets? via openalex
- Differential macrophage infiltration in early and advanced endometriosis and adjacent peritoneum via openalex
- Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis via openalex
- Endometriosis and infertility: pathophysiology and management via openalex
- Erastin induces ferroptosis via ferroportin-mediated iron accumulation in endometriosis via openalex
- Evaluation of M1 and M2 macrophages in ovarian endometriomas from women affected by endometriosis at different stages of the disease via openalex
- Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target via openalex
- Influence of race/ethnicity on prevalence and presentation of endometriosis: a systematic review and meta-analysis via openalex
- Mitochondria and oxidative stress in ovarian endometriosis via openalex
- Nonsurgical mouse model of endometriosis-associated pain that responds to clinically active drugs via openalex
- Oxidative phosphorylation inhibitors inhibit proliferation of endometriosis cells via openalex
- Pregnancy outcomes in women with endometriosis: a national record linkage study via openalex
- Subpopulations of macrophages within eutopic endometrium of endometriosis patients via openalex
- Target identification and drug discovery by data-driven hypothesis and experimental validation in ovarian endometriosis via openalex
- The endometrial immune environment of women with endometriosis via openalex
- The role and potential treatment of macrophages in patients with infertility and endometriosis via openalex
- W3165294846 via openalex
- W3167568341 via openalex
- W3171454144 via openalex
- W3180924034 via openalex
- W3181626849 via openalex
- W3199435130 via openalex
- W3217589610 via openalex
- W4226262594 via openalex
- W4234160457 via openalex
- W4285286591 via openalex
- W4322758207 via openalex
- W4366483356 via openalex
- W4386946055 via openalex
- W4393156741 via openalex
- W4397021892 via openalex
- W4407562939 via openalex
- W2003454094 via openalex
- W2012417909 via openalex
- W2027006435 via openalex
- W2486415076 via openalex
- W2588487069 via openalex
- W2626989920 via openalex
- W2765132620 via openalex
- W2807172649 via openalex
- W2809650769 via openalex
- W2899159598 via openalex
- W2902979156 via openalex
- W2937077699 via openalex
- W3033331291 via openalex
- W3095704564 via openalex
- W3105417348 via openalex
Cited by (1)
Source provenance
- europepmc
- last seen: 2026-10-15T06:08:49.021275+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-15T06:04:44.095705+00:00
- unpaywall
- last seen: 2026-10-15T06:24:24.424788+00:00
License: CC0
· commercial use OK